Publication Cover
Synthetic Communications
An International Journal for Rapid Communication of Synthetic Organic Chemistry
Volume 48, 2018 - Issue 23
272
Views
9
CrossRef citations to date
0
Altmetric
Articles

Antihyperglycemic activity of chalcone based novel 1-{3-[3-(substituted phenyl) prop-2-enoyl] phenyl} thioureas

, , , , , & show all
Pages 3015-3024 | Received 07 Aug 2018, Published online: 22 Nov 2018
 

Abstract

The present study describes the synthesis of novel chalcone based 1-{3-[3-(substituted phenyl) prop-2-enoyl] phenyl} thioureas (4a-c) using Claisen Schmidt condensation and investigates their protective role in diabetic conditions and associated oxidative stress. Spectral properties for the synthesized compounds were studied. Novel compounds were screened for antihyperglycemic effect in streptozotocin (STZ)-induced diabetic rats in a 6 week study and compound 4b exhibited significant (p ≤ .05) results similar to the standard drug glipizide. Treatment of diabetic animals with compound 4b (10 and 20 mg/kg, body weight) for 12 weeks, reduced the increased blood glucose level significantly (p ≤ .01) and restored attenuated serum biochemical parameters to normal levels. Altered antioxidant enzyme activity was also considerably (p ≤ .01) restored to the standard normal range. β-apoptotic TUNEL assay indicated that compound 4b (AI: 1.2 ± 0.05) could prevent further β-cell death in the pancreas of diabetic animals in a dose-dependent manner, which highlights its potentiality as an effective antihyperglycemic agent.

Graphical Abstract

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.